Better understanding of the health care costs of lung cancer and the implications

Leidl, Reiner; Wacker, Margarethe; Schwarzkopf, Larissa

doi:10.1586/17476348.2016.1149064

Cited by 9 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2016, it was reported that tracheal, bronchus, and lung (TBL) cancer accounted for 36 of the 213 million disability-adjusted life-years (DALYs) and 19% of all cancer deaths, making it the leading cause of DALYs and cancer-related death globally. 1,2 The costs associated with lung cancer according to the 2011 European Lung White book are 3.35 billion Euros among European countries 3 with prevalence costs of 12.1 billion dollars in the United States of America in 2010. 4 Importantly, costs of TBL cancer care are increasing for the nationwide economy and the individual patient, with government organizations paying smaller and smaller portions of TBL cancer treatment over time.…”

Section: Introductionmentioning

confidence: 99%

Burden of Tracheal, Bronchus, and Lung Cancer and Its Attributable Risk Factors in 204 Countries and Territories, 1990 to 2019

Safiri

Sohrabi

Carson‐Chahhoud

et al. 2021

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Introduction: Understanding trends in the annual incidence, mortality, and disability-adjusted life-years (DALYs) for tracheal, bronchus, and lung (TBL) cancer globally is important to enable appropriate targeting of resources for prevention, clinical practice improvement, and research. The aim of this study was to determine the global, regional, and national burdens of TBL cancer in 204 countries and territories from 1990 to 2019 by age, sex, and sociodemographic index.Methods: Estimates were produced through various data inputs including the following: cancer registries (n site-years ¼ 5318), vital registration (n site-years ¼ 22,553), vital registration-sample (n site-years ¼ 825), and verbal autopsies (n site-years ¼ 516). Annual incidence, mortality, and DALYs were estimated and presented as counts and agestandardized rates per 100,000 population.

show abstract

Section: Introductionmentioning

confidence: 99%

Burden of Tracheal, Bronchus, and Lung Cancer and Its Attributable Risk Factors in 204 Countries and Territories, 1990 to 2019

Safiri

Sohrabi

Carson‐Chahhoud

et al. 2021

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…Although medical imaging is a largely used strategy to screen lung cancer, an increasing number of NSCLCs can be diagnosed at the initial phase, and the case fatality rate for NSCLC is still high [ 4 ]. Due to the massive population base, the increasing number of smokers, and high health care costs in some countries, a majority of people are diagnosed with late-stage disease [ 5 , 6 ]. Therefore, although many treatment approaches have been developed for NSCLC, the therapeutic outcomes are not optimal [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

SRCIN1 Regulated by circCCDC66/miR-211 Is Upregulated and Promotes Cell Proliferation in Non-Small-Cell Lung Cancer

Hong

Zhuang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

The incidence and mortality of lung cancer were extremely high. The present study showed that SRCIN1 was an oncogene in non-small-cell lung cancer (NSCLC). Public dataset analysis showed SRCIN1 was significantly overexpressed in NSCLC samples. Also, we found that NSCLC patients with higher SRCIN1 expression had shorter OS time by analyzing TCGA, Kaplan-Meier Plotter, GSE30219, GSE50081, and GSE19188 databases. Overexpression or knockdown of SRCIN1 significantly induced or reduced A549 and H1299 cell proliferation. Furthermore, we found SRCIN1 was directly targeted by miR-211. Overexpression or knockdown of miR-211 suppressed or induced SRCIN1 levels in NSCLC. Moreover, we found that miR-211 affected NSCLC cell proliferation through SRCIN1. Previous studies demonstrated that circRNAs could act as miRNA sponges in cancer cells. In this study, we showed that knockdown of circCCDC66 induced expression of miR-211. Luciferase assay demonstrated that miR-211 suppressed the activity of luciferase reporter-contained circCCDC66 sequences. Moreover, knockdown of circCCDC66 significantly inhibited SRCIN1 levels in both A549 and H1299 cells. These results showed that circCCDC66 acted as a miRNA sponge to affect the miR-211/SRCIN1 axis. Of note, we for the first time revealed that circCCDC66 suppression reduced cell proliferation by about 65% in A549 and by about 40% in H1299 cells. We thought this study could provide novel potential biomarkers for NSCLC.

show abstract

“…6 Although the clinical burden of the disease is well understood, reliable estimates of the economic burden of aNSCLC to society in Europe are lacking since the cost estimates are not based on detailed real-world evidence (RWE). 7 Consequently, the direct costs incurred by aNSCLC are unknown, and information on the drivers of costs is scarce. The LENS study (Leading the Evaluation of Non-squamous and Squamous NSCLC) aimed to quantify real-world health care resource utilization (HCRU) related to aNSCLC and their associated costs of patients with squamous (SQ) and non-squamous (NSQ) aNSCLC who received two or more lines of treatment (2L+) in seven European countries.…”

Section: Introductionmentioning

confidence: 99%

<p>Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe</p>

Verleger¹,

Penrod²,

Daumont³

et al. 2020

CEOR

View full text Add to dashboard Cite

Purpose: Advanced non-small-cell lung cancer (aNSCLC; stage IIIB/IV) presents a substantial clinical burden to society; reliable estimates of its economic burden are lacking. Therefore, this study aimed to quantify real-world health care resource utilization (HCRU) and costs of patients with squamous (SQ) and non-SQ (NSQ) aNSCLC who received two or more lines of treatment (2L+) in Europe, and to describe cost-predictors. Methods: The LENS (Leading the Evaluation of Non-squamous and Squamous NSCLC) retrospective chart review study collected data from 2L+ patients with aNSCLC diagnosed between 07/2009 and 08/2011 (wave 1) or 07/2010 and 09/2012 (wave 2) in France, Germany, Italy, Spain, England, the Netherlands, and Sweden. Patients were followed from diagnosis through most recent visit/death. A weighted average of countryspecific unit costs (2018 Euro) was applied to systemic anti-cancer therapy usage and HCRU (hospital/emergency department visit, surgery, radiotherapy, ancillary care, biomarker testing) to determine the total cost from aNSCLC diagnosis to death. Generalized linear models (gamma distribution, log link) were used to assess clinical and demographic predictors. Results: Of 973 2L+ aNSCLC patients, median overall survival (OS) was 1.5 years from advanced diagnosis (range: 0.2-5.3; median OS: 1.4 [SQ], 1.6 [NSQ]), 79.0% died during follow-up. Weighted mean total per-patient costs were €21,273, ranging from €17,761 (England) to €30,854 (Sweden), and €15,446 (SQ) to €26,477 (NSQ). Systemic drug costs comprised 77.4% of total costs. Insurance status, presence of epidermal growth factor receptor (EGFR) mutation, SQ histology, age, alcohol abuse, and year of diagnosis were significant predictors for lower total costs per patient-month, Eastern Cooperative Oncology Group performance status (ECOG PS) ≥1 and country for higher costs. Conclusion: In the era pre-immunotherapy, HCRU and costs were substantial in aNSCLC 2L+ patients, with most of the costs accrued prior to start of 2L. NSQ patients incurred significantly higher total costs than SQ patients in all participating countries.

show abstract

Better understanding of the health care costs of lung cancer and the implications

Cited by 9 publications

References 14 publications

Burden of Tracheal, Bronchus, and Lung Cancer and Its Attributable Risk Factors in 204 Countries and Territories, 1990 to 2019

Burden of Tracheal, Bronchus, and Lung Cancer and Its Attributable Risk Factors in 204 Countries and Territories, 1990 to 2019

SRCIN1 Regulated by circCCDC66/miR-211 Is Upregulated and Promotes Cell Proliferation in Non-Small-Cell Lung Cancer

<p>Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe</p>

Contact Info

Product

Resources

About